BioCryst Pharmaceuticals (MEX:BCRX) FFO per Share


MEX:BCRX BioCryst Pharmaceuticals Inc MEX:BCRX
56 GF Score
Price MXN182.00
GF Value MXN218.05
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals FFO per Share?

FFO per Share only applies to REITs.

MEX:BCRX
56GF Score
BioCryst Pharmaceuticals Inc MEX:BCRX
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioCryst Pharmaceuticals (MEX:BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of MXN182.00 is trading 16.5% below its estimated GF Value™ of MXN218.05. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MEX:BCRX:

  • FFO per Share:
  • GF Value™: MXN218.05 vs. price of MXN182.00 (16.5% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the MEX:BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:USABO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
56GF Score

Get the complete analysis for MEX:BCRX

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN182.00
Price
MXN218.05
GF Value